Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of
capecitabine, erlotinib hydrochloride, and bevacizumab that can be given in combination with
radiation to patients with pancreatic cancer.